Journal
JOURNAL OF THE NEUROLOGICAL SCIENCES
Volume 395, Issue -, Pages 62-70Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2018.09.033
Keywords
Mitochondria; Central nervous system; Drug delivery; Alzheimer's disease
Categories
Funding
- National Research Foundation of Korea (NRF) - Korean government [NRF-2017R1A2B4012636]
- Gachon University Research Grant [2018-0314]
Ask authors/readers for more resources
Alzheimer's Disease (AD) is one of the most common age-related neurodegenerative diseases in the developed world. Treatment of AD is particularly challenging as the drug must overcome the blood brain barrier (BBB) before it can reach its target. Mitochondria are recognized as one of the most important targets for neurological drugs as the organelle is known to play a critical role in diverse cellular processes such as energy production and apoptosis regulation. Mitochondrial targeting was originally developed to study mitochondrial dysfunction and the organelles interaction with other sub-cellular organelles. The purpose of this review is to provide an overview of mitochondrial dysfunction and its role in late onset AD pathology. We then highlight recent antioxidant and enzymatic treatments used to alleviate mitochondrial dysfunction. Finally, we describe current applications of targeted mitochondrial delivery in the treatment of AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available